Crescent Biopharma(CBIO)

WALTHAM, MAPharmaceutical1 H-1B visas (FY2023)

Focus: Crescent Biopharma is a public oncology-focused pharmaceutical company headquartered in Waltham, MA, founded in 2016 and trading on NASDAQ under ticker CBIO. The company operates as a mid-cap biotech with a nascent pipeline centered on solid tumor therapeutics.

Oncology

Profile data last refreshed 1h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

12-1 this month

Stable — net -1 jobs in 30d

5 added, 6 removed. Backfill posture.

Should You Work at Crescent Biopharma?

AI assessment

Crescent is a high-risk, early-stage oncology play suitable only for scientists and operators comfortable with pre-commercial biotech volatility and willing to bet on CR-001's clinical success as existential catalyst.

Why Work Here

Public company status provides liquidity and equity upside potential—13 active job openings suggest active hiring and growth investment

Data completeness

5/9 — Partial

Company HealthStrong

Pipeline

Early-stage

9 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$0K

Pipeline & Clinical Trials

Folic acid

Acute Myocardial Infarction

N/A

Clinical Trials (1)

NCT00266487The Norwegian Vitamin Trial (NORVIT)

N/A

Help build intelligence for Crescent Biopharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Oncology focus aligns with highest-value therapeutic area; CR-001 Phase 1/2 program in solid tumors represents core bet

Strong cash position of $35M (FY 2025) and $42M (FY 2024) provides near-term runway; H1B approval rate is 100% (1 approval, 0 denials in 2023)

Watch Out For

Early-stage pipeline: only 1 Phase 1/2 program (CR-001); no Phase 3 programs, no approved products, and no significant revenue ($10K in FY 2024) signal minimal commercial infrastructure and long value-creation timeline
Significant cash burn: FY 2025 net loss of $17.9M and FY 2024 net loss of $36.9M against modest cash reserves means limited runway (likely 1–2 years at current burn) without financing or revenue inflection

Generated by Claude from Crescent Biopharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Infected

Wounds and Injuries

N/A

Clinical Trials (1)

NCT03463720Outcome for Patients With War-Associated Extremity Wound Infection

N/A

Maternal Neonatal and Child Health Interventions

Antepartum Hemorrhage

N/A

Clinical Trials (1)

NCT02797353Strengthening Maternal Neonatal and Child Health Services in a Rural District of Pakistan

N/A

Specialized Training Course in Disaster and Emergency Medicine

Disaster Medicine Education and Preparedness Among Medical Students

N/A

Clinical Trials (1)

NCT07293572Disaster Medicine Training for Pre-Clinical Medical Students at the University of Tripoli, Libya

N/A

Motivational interview

Codependency, Psychological

N/A

Clinical Trials (1)

NCT05324644The Effect of Motivational Interview Attempt on Self-Efficacy Level and Decision to Quit Smoking of University Students

N/A

Self Help Plus

Stress, Psychological

N/A

Clinical Trials (1)

NCT03571347Self Help Plus for Asylum Seekers and Refugees in Europe

N/A

A Novel Method of Screening for Ovarian Cancer Using Gynecologic Fluids and Mucus

Ovarian Cancer

N/A

Clinical Trials (1)

NCT01787656A Novel Method of Screening for Ovarian Cancer Using Gynecologic Fluids and Mucus

N/A

CR-001

Locally Advanced / Metastatic Solid Tumors

PHASE_1_2

Clinical Trials (1)

NCT07335497CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1/2

Chlorhexidine

Neonatal Infections

PHASE_4

Clinical Trials (1)

NCT02279381Neonatal Package Study in Rural District of Pakistan

Phase 4

Interview Prep Quick Facts

Founded: 2016

Portfolio: 9 clinical trials

Top TAs: Oncology, Hematology, Infectious Diseases

H-1B (2023): 1 approval

Publications: 2 in PubMed

SEC Filings: 2 available

Open Roles: 12 active jobs

Therapeutic Area Focus

Oncology

2 pipeline

Hematology

1 pipeline

Infectious Diseases

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$0100%

R&D Spend

$14M30%

Net Income

-$18M

Cash

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Research Publications(2)

Recent peer-reviewed publications with author affiliations at this company

The IgG-degrading enzyme of Streptococcus pyogenes causes rapid clearance of anti-glomerular basement membrane antibodies in patients with refractory anti-glomerular basement membrane disease.

Kidney international

2019

PMID:31563334

Rapid establishment of the European Bank for induced Pluripotent Stem Cells (EBiSC) - the Hot Start experience.

Stem cell research

2017

PMID:28334554

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Crescent Biopharma(CBIO)

Should You Work at Crescent Biopharma?

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Recent News · Crescent Biopharma(10)

Open Jobs (12)

Senior Manager, Corporate Communications & Investor Relations

Senior Director, Quality Control

Senior Scientist, Translational Research (Immunohistochemistry)

Director, Program Management

Senior Manager / Associate Director, Clinical Sample Operations

Director, Talent Acquisition

Executive Director/Vice President, Corporate Development

Executive Assistant - R&D

Vice President, Pharmacovigilance

Vice President, Program Team Leader

Executive Director, Regulatory Affairs CMC

Executive Director/Vice President, Medical Lead

Financials (FY2025)

Hiring Trend

Visa Sponsorship

Research Publications(2)